[Observation on effect of supplementary treatment by Astragalus injection in treating senile pulmonary tuberculosis patients].

OBJECTIVE: To observe the clinical therapeutic supplementary effect of Astragalus injection (ASI) as anti-tuberculosis agents in treating senile tuberculosis (ST). METHODS: Seventy-six ST patients were divided according to their hospitalization order into two groups randomly, 39 in the ASI group and 37 in the control group. The anti-tuberculosis regimen applied on all patients were HRE (S)Z for first treated patients and KHZ1321 TH for retreated patients. In the ASI group, ASI was given additionally by adding ASI 20 ml into 500 ml 5% glucose solution for intravenous dripping, once a day. The therapeutic course was 2 months. The changes of focal size, bacteria in sputum, and erythrocyte immune function (EIF) were observed before and after treatment, and the EIF obtained from 30 healthy subjects was taken for control. RESULTS: EIF in patients of both groups was lower than that in healthy subjects (P < 0.01). Rosette rate of RBC-C3b receptor in both groups was all increased after treatment, the increment was higher in the ASI group than that in the control group significantly (P < 0.01). After 2 months ASI treatment, the effective rate of focal absorption examined by X-ray was 84.6% and the negative conversion rate of bacteria in sputum was 79.4%. CONCLUSION: ASI has the effect of elevating erythrocyte immunity in senile pulmonary tuberculosis patients, it is able to enhance the therapeutic effect of treatment.

[Studies on the chemical constituents from the skin of Bufo bufo gargarizans Cantor].

Four bufotoxins were isolated by means of preparative reversed phase HPLC from the water soluble fraction of the skin of Bufo bufo gargarizans Cantor. On the basis of their spectral data (UV, IR, 1HNMR, 13CNMR, EIMS and FDMS), amino acid analyses and chemical properties, they were identified as bufotalin 3-succinoylarginine ester(I), bufalin 3-succinoylarginine ester(II), cinobufagin 3-succinoylarginine ester(III), and resibufogenin 3-succinoylarginine ester(IV). Compound I is a new bufotoxin.